These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 38751556)
1. Genetic/Epigenetic Alteration and Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Transforming the Immune Microenvironment with Molecular-Targeted Agents. Nishida N; Kudo M Liver Cancer; 2024 Apr; 13(2):136-149. PubMed ID: 38751556 [TBL] [Abstract][Full Text] [Related]
2. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893 [TBL] [Abstract][Full Text] [Related]
3. Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma. Zhang Z; Wang G; Du L; Zhao J; Pan L; Zhang G; Wang F; Liu R Front Immunol; 2023; 14():1124482. PubMed ID: 37292215 [TBL] [Abstract][Full Text] [Related]
4. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? Aitcheson G; Mahipal A; John BV Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096 [No Abstract] [Full Text] [Related]
6. Non-Inflamed Tumor Microenvironment and Methylation/Downregulation of Antigen-Presenting Machineries in Cholangiocarcinoma. Nishida N; Aoki T; Morita M; Chishina H; Takita M; Ida H; Hagiwara S; Minami Y; Ueshima K; Kudo M Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190307 [TBL] [Abstract][Full Text] [Related]
7. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma. Xu L; Zhang Y; Lin Z; Deng X; Ren X; Huang M; Li S; Zhou Q; Fang F; Yang Q; Zheng G; Chen Z; Wu Z; Sun X; Lin J; Shen J; Guo J; Li X; Xue T; Tan J; Lin X; Tan L; Peng H; Shen S; Peng S; Li S; Liang L; Cleary JM; Lai J; Xie Y; Kuang M J Hepatol; 2024 Mar; ():. PubMed ID: 38508240 [TBL] [Abstract][Full Text] [Related]
8. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030 [TBL] [Abstract][Full Text] [Related]
9. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. Moeini A; Sia D; Bardeesy N; Mazzaferro V; Llovet JM Clin Cancer Res; 2016 Jan; 22(2):291-300. PubMed ID: 26405193 [TBL] [Abstract][Full Text] [Related]
10. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors. Wu T; Jiang X; Zhang X; Wu B; Xu B; Liu X; Zheng L; Wang Y Cancer Control; 2021; 28():1073274821989314. PubMed ID: 33618536 [TBL] [Abstract][Full Text] [Related]
11. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Wabitsch S; Tandon M; Ruf B; Zhang Q; McCallen JD; McVey JC; Ma C; Green BL; Diggs LP; Heinrich B; Greten TF Cell Mol Gastroenterol Hepatol; 2021; 12(3):1166-1178. PubMed ID: 34033968 [TBL] [Abstract][Full Text] [Related]
12. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508 [TBL] [Abstract][Full Text] [Related]
17. Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma. Chung T; Park YN Front Med (Lausanne); 2022; 9():857140. PubMed ID: 35433771 [TBL] [Abstract][Full Text] [Related]
19. Correlation of Vein-Rich Tumor Microenvironment of Intrahepatic Cholangiocarcinoma With Tertiary Lymphoid Structures and Patient Outcome. Doi N; Ino Y; Fuse M; Esaki M; Shimada K; Hiraoka N Mod Pathol; 2024 Feb; 37(2):100401. PubMed ID: 38043787 [TBL] [Abstract][Full Text] [Related]
20. The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting. Salati M; Caputo F; Baldessari C; Carotenuto P; Messina M; Caramaschi S; Dominici M; Bonetti LR Cancer Manag Res; 2021; 13():7747-7757. PubMed ID: 34675670 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]